NCT05411718 is a Phase 2 clinical trial of Naproxen in T Cells, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05411718?

NCT05411718 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05411718?

Interventions in NCT05411718: Naproxen, Aspirin.

What condition does NCT05411718 study?

NCT05411718 studies T Cells, Colorectal Cancer, Lynch Syndrome.

Is NCT05411718 still recruiting?

NCT05411718 is currently recruiting now. Last updated 13 November 2025.

Last reviewed 2025-11-13 · How we verify

NCT05411718

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

Recruiting now Phase 2 Last updated 13 November 2025

What this trial tests

Phase 2 trial testing Naproxen in T Cells in 40 participants. Currently enrolling.

Timeline

21 March 2023

Primary endpoint
30 November 2026

30 November 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	40
Start date	21 March 2023
Primary completion	30 November 2026
Estimated completion	30 November 2026
Sites	1 location across United States

Drugs / interventions tested

Naproxen (naproxen) — full drug profile →
Aspirin — full drug profile →

Conditions studied

T Cells — all drugs for T Cells →
Colorectal Cancer — all drugs for Colorectal Cancer →
Lynch Syndrome — all drugs for Lynch Syndrome →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with T Cells or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To learn about the effects of naproxen and aspirin on the normal colon in people with Lynch Syndrome.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Past and Future of Inflammation as a Target to Cancer Prevention.
Antonucci L, Karin M. · · 2024 · cited 9× · PMID 38271694 · DOI 10.1158/1940-6207.capr-23-0423
Gold(I) Complexes Based on Nonsteroidal Anti-Inflammatory Derivatives as Multi-Target Drugs against Colon Cancer.
Saez J, Quero J, Rodriguez-Yoldi MJ, Gimeno MC, et al · · 2024 · cited 6× · PMID 39389034 · DOI 10.1021/acs.inorgchem.4c02988

Verify or expand the search:

Other trials of Naproxen

Trials testing the same drug.

NCT07277712 — A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers · Phase 1 · not yet recruiting
NCT07204379 — Effect of Oral Analgesics on Post-op Pain · EARLY_PHASE1 · completed
NCT06948513 — Effect of Over-the-counter Analgesics on Postoperative Pain · Phase 3 · completed
NCT05237297 — Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole · Phase 1 · completed
NCT03771612 — Inflammation and Daily Life Study · EARLY_PHASE1 · completed

Other recruiting trials for T Cells

Currently open trials in the same condition.

NCT07375420 — Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer? · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05411718 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 13 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05411718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing